共 50 条
- [31] Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLCJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S25 - S25Cho, Byoung ChulDy, Grace K.Kim, Tae MinSarker, DebashisHamid, OmidWilliamson, Stephen K.Kim, Sang-WeHusain, HatimChen, ShuquanMani, JayakumarJankovic, VladimirPaccaly, AnneMasinde, SheilaLowy, IsraelBrennan, LauraGullo, Giuseppe
- [32] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Yang, YunpengChen, YuQu, SongLiu, LeiChen, LishaYang, KunyuHuang, XiaomingLi, JingaoWang, RenshengZhu, HaishengZhao, ShiweiLi, TaoCai, ShengliZhang, Li
- [33] IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation studyJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Xu, NongMao, ChenyuQian, JiongZheng, YulongJiang, HaipingGao, YuanXiao, ChengXiong, AnwenLi, WeiHe, YayiRen, ShengxiangWang, LeiYu, JiaZhu, JunLiu, YingZhou, Caicun
- [34] Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Bai, XueLi, MeiChen, YuSi, LuChen, JingPu, XingxiangCheng, YingZou, ZhengyunZhao, ShiweiLi, TaoCai, ShengliGuo, Jun
- [35] Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced NonSquamous NSCLCJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S660 - S660Vokes, N.Paz-Ares, L.Cappuzzo, F.Yamamoto, N.Gray, J. E.Owonikoko, T.Ariyasu, R.Ishii, H.Kang, J. H.Lee, S. -H.Hallwachs, R.Coenen-Stass, A.Sarholz, B.Pudelko, L.Mukker, J. KaurMoulin, C.Gounaris, I.Villaruz, L. C.
- [36] A Phase 2/3 Study of Fianlimab plus Cemiplimab versus Cemiplimab in Patients with Advanced NSCLC with Tumors Expressing PD-L1 ≥50%JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E39 - E39Faulkner, NeilNair, SantoshGabrail, NashatKunta, GopalIbrahim, EmadDreisbach, LukeBrungs, DanielMani, JayakumarGhattas, MariaLi, SiyuSalvati, MarkLowy, IsraelHiley, TaraFury, Matthew G.Paoluzzi, Luca
- [37] Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade is associated with induction of pro-inflammatory TregsJOURNAL OF IMMUNOLOGY, 2022, 208 (01):Rolig, Annah S.Sturgill, Elizabeth R.Mick, CourtneyRose, DanielKaufmann, JohannaYanamandra, NiranjanGriffin, SueSmothers, JamesRedmond, William L.
- [38] Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Liu, JiayongTan, ZhichaoFan, ZhengfuBai, ChujieXue, RuifengLi, ShuGao, TianZhang, LuWang, Xinyu
- [39] TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti-PD-1, anti-LAG-3, and anti-TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Miller, Natalie J.Ambrazeviciute, GreteChen, WenwenDakhil, Sumia N.Gaylord, EricaHall, Evan ThomasMajovski, JuliaHerrin, ZacharyKiriluk, SamanthaNghiem, PaulNguyen, VivianPerdue, AndreaPulliam, ThomasTachiki, Lisa May LingVeatch, JoshuaBhatia, Shailender
- [40] Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade (ICB) is associated with induction of pro-inflammatory TregsJOURNAL OF IMMUNOLOGY, 2020, 204 (01):Sturgill, Elizabeth RowlandMick, CourtneyKaufmann, Johanna K.Redmond, William L.